The FDA has approved the Barostim Neo System, from CVRx, for the improvement of symptoms in patients with advanced heart...
Boston Scientific Corporation has announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on...
Essential hypertension The mechanism whereby the thiazides exert their antihypertensive effect has not been clearly established. In non-oedematous patients there may be little noticeable diuretic effect. Neo-Naclex-K may be used as the sole anti-hypertensive agent, or as an adjunct to other anti-hypertensive drugs whose action may be enhanced. Oedema. Neo-Naclex-K inhibits the renal tubular absorption of salt and water by its action at the beginning of the distal convoluted tubule. Sodium and chloride ions are excreted in equivalent proportions. Because potassium excretion is promoted, metabolic alkalosis may occur secondary to hypokalaemia. There is no important effect upon carbonic anhydrase. Neo-Naclex-K causes a steady diuresis lasting about 12 hours. It is indicated in the treatment of oedema associated with conditions such as congestive heart failure, nephrotic syndrome and cirrhosis of the liver.
BioNTech and Neon Therapeutics, Inc. announced that they have entered into a definitive merger agreement under which BioNTech will acquire...
Boston Scientific Corporation announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2 Aortic Valve System .
Addisonian pernicious anaemia. Prophylaxis and treatment of other macrocytic anaemias associated with vitamin B 12 deficiency. Tobacco amblyopia and Leber's optic atrophy.
The general purpose of the study is evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention in the context of the Unified Health System in Brazil.